Cat. No. | Especies | Descripción del producto | Estructura | Pureza | Característica |
---|---|---|---|---|---|
TR2-C52H7 | Cynomolgus | Cynomolgus TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
TR2-M52H5 | Mouse | Mouse TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag | ![]() |
![]() ![]() |
|
TR2-H82E6 | Human | Biotinylated Human TRAIL R2 / DR5 / TNFRSF10B Protein, Avitag™,His Tag (MALS verified) | ![]() |
![]() ![]() |
|
TR2-H5255 | Human | Human TRAIL R2 / DR5 / TNFRSF10B Protein, Fc Tag | ![]() |
![]() ![]() |
|
TR2-H5229 | Human | Human TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag | ![]() |
![]() ![]() |
Loaded Human TRAIL R2, Fc Tag (Cat. No. TR2-H5255) on AHC Biosensor, can bind Human TRAIL, His Tag with an affinity constant of 0.146 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Aponermin | Approved | Beijing Shadong Biotech Co Ltd | 沙艾特 | Mainland China | Multiple Myeloma | Wuhan Hiteck Biological Pharma Co Ltd | 2023-11-02 | Multiple Myeloma | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Dulanermin (Shanghai GeBaiDe) | Phase 3 Clinical | Shanghai Gebaide Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | |
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech) | Phase 3 Clinical | Shenzhen Sinobioway Xinpeng Biomedicine Co Ltd | Neoplasms | Details | |
IBI-3004 | IBI-3004; IBI3004 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Colorectal Neoplasms | Details |
Rilunermin alfa | SCB-313 (TRAIL-Trimer) | Phase 1 Clinical | Hydrothorax; Ascites; Peritoneal Neoplasms; Pleural Effusion, Malignant | Details | |
BI-905711 | BI-905711 | Phase 1 Clinical | Boehringer Ingelheim Gmbh | Pancreatic Neoplasms; Cholangiocarcinoma; Gastrointestinal Neoplasms | Details |
Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma) | CTB-006 | Phase 1 Clinical | Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi, Lonn Ryonn Pharma Ltd | Solid tumours | Details |
Ozekibart | JCT-205; INBRX-109 | Phase 1 Clinical | Inhibrx Inc | Adenocarcinoma | Details |
Oba-01 | Oba-01; Oba01 | Phase 1 Clinical | Yantai Heyuanaidisi Biomedical Technology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
DS-8273 | DS-8273; DS-8273a | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Colorectal Neoplasms; Lymphoma; Melanoma | Details |
Aplitabart | IGM-8444 | Phase 1 Clinical | Igm Biosciences Inc | Solid tumours; Chondrosarcoma; Sarcoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
This web search service is supported by Google Inc.